Therapeutic options for CTLA-4 insufficiency.

Egg D., Rump I. C., Mitsuiki N., Rojas-Restrepo J., Maccari M., Schwab C., ...Daha Fazla

The Journal of allergy and clinical immunology, cilt.149, ss.736-746, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 149
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.jaci.2021.04.039
  • Dergi Adı: The Journal of allergy and clinical immunology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.736-746
  • Anahtar Kelimeler: CTLA-4, common variable immunodeficiency, primary immunodeficiency, diagnosis, treatment, abatacept, sirolimus, LRBA, rituximab, HSCT, IMMUNE DYSREGULATION, MANAGEMENT, RITUXIMAB, DEFICIENCY, MUTATIONS, DISEASE
  • Marmara Üniversitesi Adresli: Evet

Özet

Background: Heterozygous germline mutations in cytotoxic T lymphocyte-associated antigen-4 (CTLA4) impair the immunomodulatory function of regulatory T cells. Affected individuals are prone to life-threatening autoimmune and lymphoproliferative complications. A number of therapeutic options are currently being used with variable effectiveness.